Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: The fracture intervention trial

The WHO Fracture Risk Assessment Tool (FRAX; http://www.shef.ac.uk/FRAX) estimates the 10‐year probability of major osteoporotic fracture. Clodronate and bazedoxifene reduced nonvertebral and clinical fracture more effectively on a relative scale in women with higher FRAX scores. We used data from the Fracture Intervention Trial (FIT) to evaluate the interaction between FRAX score and treatment with alendronate. We combined the Clinical Fracture (CF) arm and Vertebral Fracture (VF) arm of FIT. The CF and VF arm of FIT randomized 4432 and 2027 women, respectively, to placebo or alendronate for 4 and 3 years, respectively. FRAX risk factors were assessed at baseline. FRAX scores were calculated by WHO. We used Poisson regression models to assess the interaction between alendronate and FRAX score on the risk of nonvertebral, clinical, major osteoporotic, and radiographic vertebral fractures. Overall, alendronate significantly reduced the risk of nonvertebral fracture (incidence rate ratio [IRR] 0.86; 95% confidence interval [CI], 0.75–0.99), but the effect was greater for femoral neck (FN) bone mineral density (BMD) T‐score ≤ −2.5 (IRR 0.76; 95% CI, 0.62–0.93) than for FN T‐score > −2.5 (IRR 0.96; 95% CI, 0.80–1.16) (p = 0.02, interaction between alendronate and FN BMD). However, there was no evidence of an interaction between alendronate and FRAX score with FN BMD for risk of nonvertebral fracture (interaction p = 0.61). The absolute benefit of alendronate was greatest among women with highest FRAX scores. Results were similar for clinical fractures, major osteoporotic fractures, and radiographic vertebral fractures and whether or not FRAX scores included FN BMD. Among this cohort of women with low bone mass there was no significant interaction between FRAX score and alendronate for nonvertebral, clinical or major osteoporotic fractures, or radiographic vertebral fractures. These results suggest that the effect of alendronate on a relative scale does not vary by FRAX score. A randomized controlled trial testing the effect of antifracture agents among women with high FRAX score but without osteoporosis is warranted. © 2012 American Society for Bone and Mineral Research.

[1]  J. Kanis,et al.  The effects of a FRAX® revision for the USA , 2009, Osteoporosis International.

[2]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[3]  Claus Christiansen,et al.  Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  J. Kanis,et al.  A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX® , 2011, Osteoporosis International.

[5]  J. Kanis,et al.  Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. , 2009, Bone.

[6]  S. Cummings,et al.  Design of the Fracture Intervention Trial , 2005, Osteoporosis International.

[7]  John Brazier,et al.  Clodronate Reduces the Incidence of Fractures in Community‐Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled Randomized Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  S. H. Kan,et al.  Epidemiology of vertebral fractures in women. , 1989, American journal of epidemiology.

[9]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[10]  B. Ettinger,et al.  Updated fracture incidence rates for the US version of FRAX® , 2009, Osteoporosis International.

[11]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[12]  S. Cummings,et al.  Estimates of the Proportion of Older White Women Who Would Be Recommended for Pharmacologic Treatment by the New U.S. National Osteoporosis Foundation Guidelines , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  J. Kanis,et al.  A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. , 2010, Bone.

[14]  H. Kang,et al.  Vertebral Fracture in Osteoporosis , 1993 .

[15]  L Abenhaim,et al.  Use of oral corticosteroids in the United Kingdom. , 2000, QJM : monthly journal of the Association of Physicians.

[16]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[17]  J. Kanis,et al.  Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.